Autopsy report · NCT03495713
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Cause of deathStaffing, sites or logistics
“Covid-19”
Life of this trial
- Registered 7 months before it started.
- Ran for about 3 years 6 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Conditions
- Hodgkin Lymphoma
- Interventions
- Nivolumab
- Participants
- 7
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.